Skip to content

Study · Non-randomized trial · n = 6 · 1981

14 results

Short-term effects of synthetic human parathyroid hormone-(1--34) administration on bone mineral metabolism in osteoporotic patients.

Slovik DM, Neer RM, Potts JT Jr

The Journal of clinical investigation1 Nov 1981Cited by 74 (Europe PMC)

PMID7298851 (opens in a new tab)PMCIDPMC370921 (opens in a new tab)DOI10.1172/jci110372 (opens in a new tab)PepBankPUB-07298851
Source linkPubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with osteoporosis, PTH slightly increased fasting plasma calcium, primarily at the higher dose.

    In plain wordsIn patients with osteoporosis, fasting blood calcium rose slightly during PTH treatment, mainly at the higher dose.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFasting plasma calcium
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    450 or 750 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    The mean fasting plasma calcium values rose slightly after hPTH-(1--34) administration, primarily in the high-dose group.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with osteoporosis, mean fasting plasma inorganic phosphate did not differ during PTH treatment.

    In plain wordsIn patients with osteoporosis, fasting blood phosphate did not differ during PTH treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFasting plasma phosphate
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    450 or 750 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    There was no difference in the mean fasting plasma inorganic phosphate levels.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with osteoporosis, calcium kinetic studies showed a minimal increase in bone accretion during PTH treatment.

    In plain wordsIn patients with osteoporosis, bone accretion increased minimally during PTH treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone accretion rate
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    450 or 750 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    47Ca kinetic studies showed a minimal increase in bone accretion rate, a decrease in the mean transit time of calcium in the exchangeable pools, and a decrease in the exchangeable-pool size.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with osteoporosis, mean calcium transit time in exchangeable pools decreased during PTH treatment.

    In plain wordsIn patients with osteoporosis, calcium transit time in exchangeable pools decreased during PTH treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCalcium transit time in exchangeable pools
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    450 or 750 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    47Ca kinetic studies showed a minimal increase in bone accretion rate, a decrease in the mean transit time of calcium in the exchangeable pools, and a decrease in the exchangeable-pool size.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with osteoporosis, calcium exchangeable-pool size decreased during PTH treatment.

    In plain wordsIn patients with osteoporosis, the exchangeable calcium pool decreased during PTH treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCalcium exchangeable-pool size
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    450 or 750 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    47Ca kinetic studies showed a minimal increase in bone accretion rate, a decrease in the mean transit time of calcium in the exchangeable pools, and a decrease in the exchangeable-pool size.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…
  6. 06HumanNon-randomized trialEfficacy outcome

    In all six patients with osteoporosis, PTH increased renal clearance of 47Ca.

    In plain wordsIn all six patients with osteoporosis, renal calcium clearance increased during PTH treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRenal calcium clearance
    Study

    n = 6

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    450 or 750 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    In all six patients there was an increased renal clearance of 47Ca as a result of hPTH-(1--34) administration.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…
  7. 07HumanNon-randomized trialEfficacy outcome

    In patients with osteoporosis, higher-dose PTH significantly increased daily urinary calcium excretion.

    In plain wordsIn patients with osteoporosis, daily urine calcium increased during higher-dose PTH treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseUrinary calcium excretion
    Study

    n: not reported in source

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    750 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    The mean daily urinary excretion of calcium and phosphate was significantly increased in patients given the higher dose.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…
  8. 08HumanNon-randomized trialEfficacy outcome

    In patients with osteoporosis, higher-dose PTH significantly increased daily urinary phosphate excretion.

    In plain wordsIn patients with osteoporosis, daily urine phosphate increased during higher-dose PTH treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseUrinary phosphate excretion
    Study

    n: not reported in source

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    750 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    The mean daily urinary excretion of calcium and phosphate was significantly increased in patients given the higher dose.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…
  9. 09HumanNon-randomized trialEfficacy outcome

    In patients with osteoporosis, PTH at 750 U increased net intestinal calcium absorption.

    In plain wordsIn patients with osteoporosis, intestinal calcium absorption increased during PTH treatment at 750 U.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseIntestinal calcium absorption
    Study

    n: not reported in source

    Outcome group
    Intestinal growth and absorption · Gastrointestinal
    Studied dose
    750 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    In patients given 750 U, net intestinal calcium absorption increased, phosphate absorption increased, calcium balance improved, and phosphate balance improved.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…
  10. 10HumanNon-randomized trialEfficacy outcome

    In patients with osteoporosis, PTH at 750 U increased phosphate absorption.

    In plain wordsIn patients with osteoporosis, phosphate absorption increased during PTH treatment at 750 U.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseIntestinal phosphate absorption
    Study

    n: not reported in source

    Outcome group
    Intestinal growth and absorption · Gastrointestinal
    Studied dose
    750 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    In patients given 750 U, net intestinal calcium absorption increased, phosphate absorption increased, calcium balance improved, and phosphate balance improved.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…
  11. 11HumanNon-randomized trialEfficacy outcome

    In patients with osteoporosis, PTH at 750 U improved calcium balance.

    In plain wordsIn patients with osteoporosis, calcium balance improved during PTH treatment at 750 U.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCalcium balance at higher dose
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    750 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    In patients given 750 U, net intestinal calcium absorption increased, phosphate absorption increased, calcium balance improved, and phosphate balance improved.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…
  12. 12HumanNon-randomized trialEfficacy outcome

    In patients with osteoporosis, PTH at 750 U improved phosphate balance.

    In plain wordsIn patients with osteoporosis, phosphate balance improved during PTH treatment at 750 U.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePhosphate balance at higher dose
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    750 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    In patients given 750 U, net intestinal calcium absorption increased, phosphate absorption increased, calcium balance improved, and phosphate balance improved.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…
  13. 13HumanNon-randomized trialEfficacy outcome

    In patients with osteoporosis, PTH at 450 U worsened calcium balance.

    In plain wordsIn patients with osteoporosis, calcium balance worsened during PTH treatment at 450 U.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCalcium balance at lower dose
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    450 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    In patients given 450 U, calcium balance and phosphate balance worsened.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…
  14. 14HumanNon-randomized trialEfficacy outcome

    In patients with osteoporosis, PTH at 450 U worsened phosphate balance.

    In plain wordsIn patients with osteoporosis, phosphate balance worsened during PTH treatment at 450 U.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreasePhosphate balance at lower dose
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    450 U/dose daily · subcutaneous · 3--4 wkAs given in this study (human).

    Source sentences

    Summary
    In patients given 450 U, calcium balance and phosphate balance worsened.
    1 context sentence
    Summary · context
    Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 g…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.